<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">After 2016, the number of ZIKV cases has decreased to the point that phase 3 field trials of the previously mentioned vaccines may be difficult or impossible to conduct.
 <xref rid="bib48" ref-type="bibr">
  <sup>48</sup>
 </xref> Nevertheless, evaluating the effectiveness of these and other vaccine candidates is essential if we are to be prepared for a reemergence of the virus. This reemergence may occur in regions with prior epidemics once population immunity wanes and/or among naive populations due to shifts in geographic range of the 
 <italic>Aedes</italic> vectors. Governmental agencies such as the US Food and Drug Administration and the European Medicines Agency are exploring pathways for regulatory approval that provide the needed flexibility to address ZIKV-specific considerations.
 <xref rid="bib48" ref-type="bibr">48</xref>, 
 <xref rid="bib81" ref-type="bibr">81</xref>
</p>
